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Purpose of Review
Insomnia is a common type of sleep disorder defined by an ongoing difficulty initiating or
maintaining sleep or nonrestorative sleep with subsequent daytime impairment. The
sleep disturbances in insomnia usually manifest as difficulty in falling asleep,
maintaining the continuity of sleep, or waking up too early in the morning well before the
desired time, irrespective of the adequate circumstances to sleep every night. Insomnia
can significantly impact daytime functioning resulting in decreased workplace
productivity, proneness to errors and accidents, inability to concentrate, frequent daytime
naps, and poor quality of life.
The treatment of insomnia should involve a multi-disciplinary approach, focusing on
implementing behavioral interventions, improving sleep hygiene, managing
psychological stressors, hypnotic treatment, and pharmacological therapy. The most
effective therapies utilize cognitive behavioral therapy in conjunction with
pharmacotherapy to minimize the needed dose and any resulting side effects.
Non-benzodiazepine hypnotics such as zolpidem, eszopiclone, zaleplon are the most used
as adjunctive treatment. One of the most used of these hypnotics is zolpidem. However,
zolpidem has a wide variety of adverse effects and has some special considerations noted
in the literature.

Recent Findings
Zolpidem has been associated with an increased risk of falls in hospitalized patients with
an OR of 4.28 (P <0.001) when prescribed short-term for insomnia. The relative risk (RR)
for hip fractures in patients taking zolpidem was described as 1.92 (95% CI 1.65-2.24;
P<0.001), with hip fractures being the most commonly seen. A case series of 119
inpatients aged 50 or older demonstrated that a majority (80.8%) of ADRs were central
nervous system (CNS)-related such as confusion, dizziness, and daytime sleepiness. A
systematic review of 24 previous studies of sleepwalking associated with zolpidem
demonstrated that the association was not dependent on age, dose, medical history, or
even a history of sleepwalking at any time before zolpidem use. Suicide attempts and
completion have been successfully linked with zolpidem use (OR 2.08; 95% CI 1.83-2.63)
in patients regardless of the presence of comorbid psychiatric illness. There have been
multiple cases reported of seizures following the withdrawal of zolpidem. Most cases have
demonstrated that withdrawal seizures occurred in patients taking daily dosages of
around 450-600mg/day, but some reported them as low as 160mg/day. Rebound insomnia
has been a concern to prescribers of zolpidem. Sleep onset latency has been demonstrated
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to be significantly increased on the first night after stopping zolpidem (13.0 minutes; 95%
CI 4.3-21.7; P<0.01). Women had a non-significantly higher mean plasma concentration
than men after 8 hours for the 10mg IR (28 vs. 20 ng/mL) and the 12.5mg MR (33 vs. 28ng/
mL). The FDA has classified zolpidem as a category C drug based on adverse outcomes
seen in animal fetal development. In the mothers exposed to zolpidem, there was an
increased incidence of low birth weight (OR = 1.39; P<0.001), preterm delivery (OR 1.49;
P<0.001), small for gestational age (SGA) babies (OR = 1.34; P<0.001), and cesarean
deliveries (OR =1.74; P<0.001). The rate of congenital abnormalities was not significantly
increased with zolpidem (0.48 vs 0.65%; P = 0.329).

Summary
Insomnia is linked to fatigue, distractibility, mood instability, decreased satisfaction, and
overall decreased quality of life. Optimal therapy can aid patients in returning to baseline
and increase their quality of life. Zolpidem is a helpful drug for the treatment of insomnia
in conjunction with cognitive-behavioral therapy. When prescribed to elderly patients,
the dose should be adjusted to account for their slower drug metabolism. Still, zolpidem is
considered a reasonable choice of therapy because it has a lower incidence of residual
daytime sleepiness and risk of falls when compared to other drugs. The most concerning
adverse effects, which are often the most publicized, include the complex behaviors that
have been seen in patients taking Zolpidem, such as sleeping, hallucinations, increased
suicidality, driving cars while asleep, and even a few cases of committing homicide. Even
so, zolpidem could be a suitable pharmacological treatment for insomnia. Decisions for
whether or not to prescribe it and the dosage should be made on a case-by-case basis,
considering both the psychical and psychiatric risks posed to the patient with insomnia
versus if the patient were to take zolpidem to treat their condition.

INTRODUCTION
Insomnia is a common type of sleep disorder that is defined
by an ongoing difficulty initiating or maintaining sleep or
nonrestorative sleep with subsequent daytime impairment.1 “Insomnia” generally refers to chronic insomnia,
characterized by symptoms persisting for greater than one
month with associated daytime dysfunction. Diagnosis is
made by taking a thorough history, including sleep, medical, psychiatric, and substance use elements. Patients
should be evaluated for comorbid conditions that could
cause insomnia or complicate treatment. Symptoms of insomnia appear in up to 50% of adult populations, with
10-15% of individuals having severe symptoms that cause
distress or impairment, meeting criteria for insomnia disorder. Risk factors include increasing age, female sex, comorbid medical conditions, shift work, and possibly low socioeconomic status and unemployment.2 This disorder is of
particular concern in the elderly population, with up to 50%
of older adults (age 65 or older) complaining of difficulty
initiating or maintaining sleep and 12 to 20% meeting criteria for diagnosis with insomnia disorder. Difficulty maintaining sleep is the most common complaint (50-70%), and
only about 50% of patients will experience remission during
the follow-up period.3 The treatment of insomnia should be
a multi-disciplinary approach, focusing on implementing
behavioral interventions, improving sleep hygiene, managing psychological stressors, hypnotic treatment, and pharmacological therapy. The most effective therapies utilize
cognitive behavioral therapy in conjunction with pharmacotherapy to minimize the needed dose and any resulting
side effects. The preferred first-line treatments include
short or intermediate-acting benzodiazepine receptor antagonists, ramelteon, sedating antidepressants, or other sedating agents such as anti-epileptic drugs and atypical an-

tipsychotics. Over-the-counter therapies such as
antihistamines, melatonin, or herbal/nutritional supplements are not recommended to treat chronic insomnia due
to lack of efficacy. Barbiturates and barbiturate-type drugs,
though previously used as a treatment for insomnia, are
also no longer recommended. When initiating pharmacologic therapy, patients should be engaged in discussion
about treatment goals, safety profiles of the drug, potential
side effects and drug interactions, alternate treatments, and
rebound insomnia. Long term medical therapy should be
monitored with careful follow-up for assessment of efficacy,
the appearance of adverse effects, and evaluation for onset
or worsening of comorbid conditions.2

INSOMNIA OVERVIEW
According to DSM-V criteria, chronic insomnia is defined
as individuals having difficulties in falling and maintaining
sleep.4 Symptoms such as early morning awakening and occurrences of fatigue, attention deficits, and mood instability throughout the day are also frequently reported.5 Such
symptoms need to persist for at least three months and
cause significant distress before a diagnosis can be confirmed.4 The sleep disturbances in insomnia usually manifest as difficulty in falling asleep, maintaining the continuity of sleep (waking up in the middle of the night and
difficulty in returning to sleep), or waking up too early in
the morning well before the desired time, irrespective of
the adequate circumstances to sleep every night.6 Insomnia
can significantly impact daytime functioning resulting in
decreased workplace productivity, proneness to errors and
accidents, inability to concentrate, frequent daytime naps,
and poor quality of life.6 Presentation is slightly different in
children and is frequently reported with symptoms including awakening at night, resisting going to bed and sleeping
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independently, and unable to sleep without proper stimulations.6 Insomnia can affect their school performance, daily
activity of playing, inability to concentrate and cause behavior problems.6
PATHOPHYSIOLOGY

The genes associated with insomnia include Apolipoprotein
(Apo) E4, PER3 (Period Circadian Regulator 3), Clock (Clock
Circadian Regulator), and 5-HTTLPR (Serotonin Transporter Linked Polymorphic Region), with a close association
between insomnia and HLA-DQB1*0602 also being reported.6 The molecular factors responsible for regulating
the sleep-wake cycle include chemicals like orexin, norepinephrine, and histamine that promote the aroused state,
whereas chemicals like GABA (Gamma Amino Butyric Acid),
adenosine, melatonin, and prostaglandin D2 promoting
sleep.6 The orexin mediated increased neuronal firing in the
wake-promoting areas (tuberomammillary nucleus, dorsal
raphe, and locus coeruleus) and inhibition of the sleeppromoting areas (ventrolateral preoptic nucleus and median preoptic nucleus) is one of the possible mechanisms
contributing to insomnia which is termed the sleep switch
model.6 Investigations of the central and autonomous nervous systems have identified the genetic explanation of insomnia etiology by suggesting an imbalance between sleepwake cycles as the final common pathway related to the
pathophysiology of chronic insomnia.4 The sleep-wake cycles are disrupted due to either the arousal systems being
overactive, the sleep-inducing systems being hypoactive, or
both.4 It is important to note that basic sleep-wake regulation is not disturbed in patients with chronic insomnia.
Instead, these patients experience a hybrid or mixed-state
sleep with ongoing signs of increased arousal, as suggested
by fine-grained analysis of the sleep EEG in these patients.4
Therefore, chronic insomnia is an imbalance in the sleepwake switch with frequent shifting to the waking state during sleep.
RISK FACTORS

Risk factors associated with the development of chronic insomnia include exposure to psychosocial factors such as
stress and predisposition to certain personality traits such
as excessive worrying, repressed personality, perfectionism,
and neuroticism.6 It is not uncommon to find patients with
chronic insomnia also suffering from other psychiatric comorbidities such as mood and anxiety disorders.6 Risk factors can be slightly different for children, as children diagnosed with chronic insomnia often have a history of delayed
milestones, hyperactive behavior, and separation anxiety.6
Increased use of alcohol and abuse/dependence on tobacco
drugs and excessive caffeine intake have also been shown to
affect the sleep-wake cycle.6,7
EPIDEMIOLOGY

Based on the criteria defined by the DSM-V for a diagnosis
of chronic insomnia, it has been estimated that the prevalence of this disorder is about 6% in the general population.8 However, at least one-third of the general population

presents with at least one symptom of chronic insomnia.7
If daytime symptoms and sleep dissatisfaction associated
with insomnia are taken into account, the prevalence increases to about 20%.7 It is essential that such distinction
be made because individuals who reported daytime symptoms and sleep dissatisfaction appeared to be more significant healthcare consumers and presented with more mental
disorders.7 Chronic insomnia has higher prevalence rates in
women than men, with the prevalence of insomnia symptoms generally increasing with age.7 Numerous factors such
as lifestyle, use of psychoactive substances, and sleep disorders have been shown to initiate or maintain insomnia;
however, the most frequently studied are mental illnesses
and organic diseases.7 A strong association between insomnia and major depressive episodes has been constantly reported in the literature. Epidemiological genetic links of insomnia are yet to be studied.7

CURRENT TREATMENT OF INSOMNIA

INITIAL NON-PHARMACOLOGIC APPROACHES

The initial approach to chronic insomnia involves behavioral interventions targeted at improving sleep hygiene.
Physicians should encourage regular exercise in young
adults with insomnia. It has been linked to an increase in
slow-wave sleep, less waking after sleep onset (WASO), and
shorter sleep onset latency (SOL).9,10 Patients should be
counseled on preventing the use of caffeine, nicotine, and
alcohol beginning six hours before bedtime. Large meals
and significant fluid intake in the evening should also be
prevented. In addition, it is essential for those with chronic
insomnia to maintain a consistent sleep-wake cycle with
circumvention of daytime napping; this is referred to as
temporal control therapy.9,11 Stimulus control therapy can
be used to help the patient associate the bedroom with
sleep and is characterized by lying down only when ready to
sleep, getting out of bed after 20 minutes of lying down if
unable to fall asleep, using the bed strictly for sleep and sex,
and waking at a similar time each day regardless of the time
of sleep onset. Patients without a history of bipolar disorder or epilepsy who spend prolonged times in bed trying to
fall asleep may benefit from sleep restriction therapy (minimum of five hours) until homeostatic sleep drive increases
and improve sleep efficiency.9,10
COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA

After failing one of the initial approaches, cognitive behavioral therapy for insomnia (CBT-I) aimed at changing
the patient’s misconceptions, beliefs, and attitudes towards
sleep is the first-line option due to its high efficacy and
lasting benefits in sleep quality.9,10,12 These effects have
been demonstrated in numerous randomized control trials
(RCTs) using polysomnography, neuropsychologic testing,
home sleep monitoring, and subjective measures.13–17 Objective measures consistently showed that CBT-I increases
N2, N3, and REM stages of sleep, while simultaneously decreasing stage N1 and wakefulness.10 A systematic review
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of 20 independent studies with a combined total of 1,162
patients revealed SOL improved by 19.03 minutes (95% CI,
14.12-23.93 min.), WASO improved by 26.00 minutes (CI
15.48-36.52 min.), and sleep efficiency improved by 9.91%
(CI 8.09-11.73%).12
CBT-I is the combination of cognitive reconstruction
with sleep hygiene interventions, stimulus control therapy,
sleep restriction therapy, and, at times, relaxation therapy.10 Relaxation techniques reduce somatic tension by
hypnosis, meditation, yoga, and progressive muscle relaxation. Autogenic training, the imagination of a calm environment with comforting bodily perceptions such as
warmth and heaviness, can be combined with imagery
training and other techniques used for relaxation. In addition, the patient can learn to control physiologic factors
such as muscle tension via visual and auditory biofeedback
therapy.9 CBT-I can also be used to aid in hypnotic discontinuation.18
NON-BENZODIAZEPINE HYPNOTICS

Certain medications can be used to augment nonpharmacologic interventions to treat insomnia, with the non-benzodiazepine hypnotics (sometimes called z-drugs) being the
most commonly used by physicians. These drugs work at
the alpha-1 subunit of the gamma-aminobutyric acid A
(GABA-A) receptor to exert their hypnotic effects by neuronal inhibition similar to benzodiazepines. RCTs have
demonstrated that these drugs significantly decreased sleep
latency compared to placebo by an average of 20 minutes
(P<0.0001) and sustained those results long-term.11,19
Zolpidem immediate release is superior at reducing sleep
latency and increasing TST out of all the z-drugs, making it
a frequent first choice medication in this group. Zolpidem
extended-release does not offer any additional benefit for
treating insomnia but may increase the risk of next-day impairment.11 Sublingual zolpidem is faster acting and more
effective at SOL reduction than the oral formulation.10 Alternatively, zaleplon has a shorter half-life. It can be used
for patients who want to take a medication upon nighttime
awakening rather than sleep maintenance before sleep onset. Eszopiclone has a longer half-life and is frequently associated with subsequent day impairment, making it the
least favorable of the group.11
ANTIDEPRESSANTS

Many patients with mood disorders experience insomnia,
and an antidepressant can be a valid option for some patients in combination with cognitive-behavioral therapy.11
Doxepin, a histamine H1 receptor antagonist, can be used at
low doses to decrease WASO (3mg and 6mg: P<0.0001), decrease SOL (3mg: P = 0.0047; 6mg: P = 0.0007), and increase
TST (3mg and 6mg: P<0.0001).10,11 At these lower doses,
the associated anticholinergic and antiadrenergic blockades
of doxepin are less significant, making the side effect profile
favorable.10 Mirtazapine can be used for older adults with
chronic insomnia and comorbid mood disorders with significantly decreased appetite and weight loss. Still, it must be
used with caution due to an elevated sedation risk.11

BENZODIAZEPINES

Once considered first-line and now falling out of favor, benzodiazepines such as temazepam and lorazepam are still
sometimes used to treat chronic insomnia. Though they are
efficacious at increasing TST and decreasing SOL, their use
is limited by adverse side effects of cognitive and respiratory depression, along with the risk of dependence and
withdrawal. These medications are reserved for intermittent and short-term use in those with insomnia refractory
to other therapeutic options.10,11
SUVOREXANT

Suvorexant, a reversible dual orexin receptor antagonist,
was approved by the FDA to treat insomnia in 2014.10,11 The
lateral hypothalamus secretes the neuropeptides orexin-A
and orexin-B, which bind their receptors in various locations of the brain to promote arousal and wakefulness.10
Suvorexant inhibits this arousal activation producing benefits of increased sleep efficiency (10mg: P<0.01; 20mg,
40mg, 80mg: P <0.001) and WASO (P<0.001 for all doses)
compared to placebo in RCTs.11,20
MELATONIN AGONISTS

Ramelteon, a melatonin agonist, is a slightly less effective
medication used to treat insomnia by reducing SOL 7.06
minutes (P<0.001), increasing TST 8.25 minutes (P=0.013)
and subjectively improving sleep quality (P<0.001) compared to placebo.11,21 It has a safe side-effect profile but is
more expensive than other therapeutic options described.
Controlled release melatonin (1-3mg) can be used but lacks
FDA approval and regulation, causing potency and drug interaction concerns.11

ZOLPIDEM
Zolpidem is a sedative-hypnotic type medication used for
the treatment of insomnia in adults. It comes in both immediate and extended-release forms; the immediate release
preparations are used to treat symptoms related to delayed
sleep onset. The extended-release preparation treats both
delayed sleep onset and decreased sleep latency. For immediate release formulations, women should be started on a
dose of 5mg and men with 5 or 10mg immediately before
bedtime. Women should begin with 6.25mg and men with
6.25mg or 12.5mg if using extended-release formulations.
In patients 65 years or older, the minimum dose should be
used to minimize adverse effects, not exceeding 5mg for
immediate release and 6.25mg for extended release. Zolpidem should only be used for short-term treatment of insomnia and should only be taken when the patient has 7 to
8 hours to sleep before being active again. Caution should
be used when prescribing this medication to patients taking
other drugs, especially medicines for seizures, sleep, anxiety, muscle relaxants, or opioids.22 Pregnant women should
only be prescribed zolpidem when potential benefits outweigh potential risks to the fetus as there are no adequate
and well-controlled studies of use in pregnant women. For
elderly or debilitated patients, the risk of impaired motor
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or cognitive performance is higher, and patients should be
monitored more closely. All patients, regardless of age,
should be monitored for adverse effects once therapy is initiated, specifically for the remission of insomnia symptoms,
abnormal thinking or behavioral changes, or severe reactions such as anaphylaxis. Patients should also be educated
on possible withdrawal effects and CNS depressant effects
resulting from the medication.23

MECHANISM OF ACTION

site. It exhibits minimal anxiolytic, myorelaxant, and anticonvulsant side effects associated with agonism at the BZ2
receptor site.26 The predominance of BZ1 receptor on structures important for regulating sleep, including Lamina IV
of the sensorimotor cortical regions, substantia nigra (pars
reticulata), cerebellum molecular layer, olfactory bulb, ventral thalamic complex, pons, inferior colliculus, and globus
pallidus, explains why zolpidem is important for the preservation of deep sleep stages 3 and 4.27

PHARMACOKINETICS

Zolpidem is a non-benzodiazepine compound that shows
a rapid-onset, short-duration hypnotic effect by binding to
benzodiazepine receptors, particularly in the cerebellum,
indicating a stronger binding preference for BZ(ω) receptors. BZ(ω) binding sites are associated with the GABAA
subtype of receptors, a ligand-gated ion channel with five
subunits for the inhibitory neurotransmitter GABA. Unlike
benzodiazepines, which bind in a non-discriminatory fashion to all BZ subtypes, zolpidem binds best to BZ(ω) receptors containing α1 subunits, evidenced by low concentrations of zolpidem potentiating the effects of GABA. In
contrast, higher concentrations of zolpidem are required to
potentiate the effects of GABA in receptors containing α2
and α3 subunits. There is little to no response in α5 containing receptors.24 Subunit binding to the GABAA receptor contributes to the sedative, anticonvulsant, anxiolytic,
and myorelaxant effects of zolpidem. The BZ(ω) receptor
is found primarily on the Lamina IV of the brain sensorimotor cortical regions, the substantia nigra pars reticulata,
the cerebellum molecular layer, the olfactory bulb, the ventral thalamic cortex, the pons, the inferior colliculus, and
the globus pallidus.25 When administered, zolpidem produces slow waves (2 to 4 Hz) on EEG with only short intervals of fast waves (12 to 14 Hz) at high doses. This effect
is preferable to benzodiazepines, which produce a greater
degree of fast-wave activity that is thought not to correspond to a pattern of normal sleep. The increase in slowwave or non-rapid eye movement sleep caused by zolpidem
has been confirmed in vivo by EEG on cats and rats. In these
studies, zolpidem increased the non-rapid eye movement
sleep with little effect on rapid eye movement sleep except
at high doses.24

PHARMACODYNAMICS
Zolpidem is an imidazopyridine used as a sleep-inducing
medication to treat chronic insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.26 It
is important to note that zolpidem is structurally different
from benzodiazepines.27 Zolpidem enhances the inhibitory
neurotransmitter γ-aminobutyric acid (GABA) activity by
selective agonism at the benzodiazepine-1 (BZ1) receptor.
This results in increased conductivity of chloride, hyperpolarization of neurons, and inhibition of the action potential, which overall decreases neuronal excitability and leads
to the sedative and hypnotic effects seen while taking this
medication.26,27 Since zolpidem is selective for the BZ1 receptor alpha1/alpha5 subunits compared to the BZ2 receptor

Zolpidem exhibits biphasic absorption characteristics
showing rapid initial absorption at the gastrointestinal tract
and extended plasma concentrations beyond three hours
after administration.CYP3A4 enzymes predominantly metabolize 26 zolpidem, and to a lesser extent, by CYP2C9,
CYP1A2, CYP2D6, and CYP2C19 enzymes.28 Zolpidem is
converted to inactive metabolites that are eliminated primarily by renal excretion.26 It has been suggested that
CYP2C9*1/*3 genotype does not affect the plasma exposure
of zolpidem.28 The mean elimination half-life of zolpidem
is 2.8 hours ranging from 1.62 to 4.05 hours.26 Food-effect
studies have suggested that administration of zolpidem immediately after a meal is associated with faster sleep onset.26 Zolpidem has shown no rebound or withdrawal effects, and individuals on the regimen have experienced
good daytime alertness.26,27 The major metabolic routes
associated with the medication are oxidation and hydroxylation.26 Zolpidem is approximately 92% bound to plasma
proteins, with absolute bioavailability of zolpidem being
approximately 70%.26,27
It is advised to reduce dosing in patients with renal and
hepatic disease and avoid zolpidem altogether in patients
with known hypersensitivity to zolpidem or any inactive
ingredients in the formulation.27 Coadministration of
haloperidol, cimetidine, ranitidine, chlorpromazine, warfarin, digoxin has not been shown to alter the pharmacokinetics of zolpidem.27 However, caution is advised for patients on Flumazenil, as it antagonizes the hypnotic effects
of zolpidem.27 Furthermore, it has been observed that volunteers treated with imipramine plus zolpidem developed
anterograde amnesia.27
The clearance of zolpidem in children is three times
higher than in young adults and is lower in the elderly.29
Hence the dosing of zolpidem should be lowered for elderly
patients. The lowering of the dose of zolpidem proves to
be beneficial for elderly individuals because they are more
likely to show symptoms of chronic insomnia. Most importantly, they are more likely to suffer from adverse side effects of medications that influence the central nervous system.29 Zolpidem is also reported to have a lower risk of
causing rebound insomnia when discontinued.29 There are
no significant differences in the pharmacokinetic parameters between various racial groups and gender.29

ADVERSE EFFECTS OF ZOLPIDEM
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FALLS AND FRACTURES

Zolpidem has been associated with an increased risk of falls
in hospitalized patients with an OR of 4.28 (P <0.001) when
prescribed short-term for insomnia.30,31 The relative risk
(RR) for hip fractures in patients taking zolpidem was described as 1.92 (95% CI 1.65-2.24; P<0.001), with hip fractures being the most commonly seen.30,32 A recent metaanalysis, including two cohort studies (OR = 2.10; 95% CI
1.76-2.49) and eight case-controls (OR = 1.53; 95% CI
1.31-1.77), demonstrated a significant association between
zolpidem and a risk of fractures separately and combined
(OR = 1.63; 95% CI 1.42-1.87). The subgroup analysis within
the study demonstrated an increased risk of fractures in
those taking z-drugs compared to a control group with insomnia (OR = 1.28; 95% CI 1.08-1.53) and even when restricted to age >65 years old (OR = 1.70; 95% CI 1.36-2.12).
Additionally, there was an association between zolpidem
use and risk of non-specific injury (OR = 2.05; 95% CI
1.95-2.15).33,34
NEUROPSYCHOLOGICAL ADVERSE EFFECTS

A systematic review and meta-analysis of 20 studies
demonstrated that zolpidem has specific adverse effects on
cognition rather than a more generalized cognitive depression seen in benzodiazepines.35 This review demonstrated
significant decreases in attention (Cohen’s d of -0.56; 95%
CI -0.93 to -0.18) and verbal memory (Cohen’s d of -0.46;
95% CI -0.66 to -0.25), compared to placebo without significant psychomotor disturbances.35 This was further corroborated by a double-blind cross-over study where zolpidem
improved critical flicker fusion (CFF) testing, a measure of
psychomotor function, compared to placebo (F=8.51,
P=0.03).36
However, caution should be used in giving zolpidem during an inpatient setting. A case series of 119 inpatients
aged 50 or older demonstrated that a majority (80.8%) of
ADRs were central nervous system (CNS)-related such as
confusion, dizziness, and daytime drowsiness. Patients with
a baseline functional impairment are at significant risk for
these CNS ADRs (P=0.003).37
Complex behaviors performed in a “sleep-like” state
have been frequently described in association with zolpidem characterized by reduced control of motor functions,
reduced awareness of one’s surroundings, difficulty thinking, amnesia, and irrational speech.38 The Therapeutic
Drugs Association (TGA) reported that 10% of the adverse
reactions with zolpidem mentioned “sleep-driving”.39
These cases were reported in both therapeutic and
supratherapeutic doses of zolpidem. Legally, the lack of
clear understanding of the patient’s awareness or volition
during this sleep-like state presents a dilemma when someone ingests zolpidem and commits a crime they do not remember. Even more perplexing is the degree of complexity
of behavior a person can complete while in this state. This
is an essential point in cases of vehicular homicide or homicide.38 There have been 5 cases of homicide linked to the
use of zolpidem in patients with concurrent mood or anxiety disorders who were taking an antidepressant.30 Four
of these cases were homicide directed at a spouse or sig-

nificant other with extreme and violent overkill in all four
cases. The final case of the five was a vehicular homicide.30
A retrospective, case-control study demonstrated a significant association of zolpidem to parasomnias (OR 4.34;
P<0.0001), amnesia (OR 2.78; P<0.0001), hallucinations (OR
1.69; P<0.0001), and suicidality (OR 1.70; P<0.0001), which
was adjusted for patient demographics and simultaneous
medication use. Movement-based parasomnias had the
strongest correlation, with an odds ratio (OR) of 34.39 (95%
CI of 31.39-37.68) when adjusted for patient demographics
and an OR of 35.20 (CI 31.65-39.14) when adjusting for
drug-exposure covariates. Between 2006 and 2009, there
was strong public scrutiny of zolpidem and associated significant increases in parasomnias (OR 7.65; P<0.05), movement-based parasomnias (OR 64.92; P<0.05), and amnesias
(OR 4.29; P<0.05). Although there was a significant association with these adverse drug reactions before the media
storm, this highlights the importance of considering notoriety bias secondary to media coverage.40
A systematic review of 24 previous studies of sleepwalking associated with zolpidem demonstrated that the association was not dependent on age, dose, medical history,
or even a history of sleepwalking at any time before zolpidem use.41 It is important to counsel patients on this, as
the product information is given with the medication only
mentions sleepwalking as a risk if combined with another
CNS depressant or at doses greater than 10mg. In this review, zolpidem was found to have the strongest association
with sleepwalking throughout the literature out of all prescribed medications included in the study.41
Suicide attempts and completion have been successfully
linked with zolpidem use (OR 2.08; 95% CI 1.83-2.63) in
patients regardless of the presence of comorbid psychiatric
illness.30,42 A review by the International Journal of Neuropsychopharmacology demonstrated that out of 23,420 dependence and withdrawal type of ADRs, 102 cases showed
intentional “self-injurious behavior” (0.5%), 44 cases included “suicidal behavior” (0.2%), and 3,101 cases were described as “suicidal attempts” (13.2%).43 Compared to zopiclone and zaleplon, zolpidem had the highest rates of fatal
outcome (20.3%) with these types of ADRs.43
ABUSE, DEPENDENCE,

& WITHDRAWAL

A significant attraction to the use of z-drugs was the expectation for lower rates of dependence, abuse, and withdrawal
than benzodiazepines. Still, studies have demonstrated that
this may not be the case. Rebound insomnia and withdrawal
symptoms have been linked to zolpidem use after stopping
the medication suddenly, even if the patient took the therapeutic dose, with an even higher risk in those with concurrent drug or alcohol dependence.43,44 Misuse-, abuse-, dependence-, and withdrawal-related ADRs have been shown
to make up 11.35% (95% CI 11.21-11.49%) of total ADRs
seen with zolpidem.
Data on dependence and abuse with zolpidem was obtained from the Center for Evaluation and Information on
Pharmacodependence (CEIP) during the post-marketing period of 2003-2010 in France and demonstrated a consistently increasing rate of “Suspect Prescriptions Possibly Indicating Abuse” during this time. Zolpidem was the drug
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most associated with these types of falsified prescriptions
in 2009. This paper compared 30 cases of dependence and
abuse in zolpidem users, finding an average age of 38 years
old and range of daily dosage being 50-2000mg (average
of 616.61mg). Concurrent disorders of substance abuse
(40.0%) and psychiatric conditions (13.3%) collectively
made up over half of the cases.45
A double-blind, placebo-controlled study was performed
on 11 healthy participants without a personal or family
substance abuse history to investigate subjective effects of
zolpidem. After receiving one of the four treatments (0, 5,
10, or 20mg zolpidem), the patients began by answering
the Addiction Research Center Inventory (ARCI). Within the
ARCI, zolpidem was noted to affect two parameters of drug
effects: intoxicating-like feelings (Pentobarbital-Chlorpromazine-Alcohol group; PCAG) and stimulating-like effects
(Benzedrine group; BG). PCAG
and BG
associated with zolpidem
were both significant. A visual analog scale (VAS) was used
to report how they were feeling at that moment, with the
most reported being “sleepy”
“high”
and “good effects”
at the highest doses. Interestingly, a choice of drug versus money ranging from $0.35 to
$10.00 always resulted in money over zolpidem.46
There have been multiple cases reported of seizures following the withdrawal of zolpidem.44,47 Most cases have
demonstrated that withdrawal seizures occurred in patients
taking daily dosages of around 450-600mg/day, but some
reported them as low as 160mg/day. All instances of withdrawal seizures from zolpidem have been successfully
treated with diazepam, a long-acting benzodiazepine,
which allows a prolonged taper of neuronal inhibition.47
Rebound insomnia has been a concern to prescribers of
zolpidem. Studies have demonstrated that the first night after discontinuation of zolpidem, there was a nonsignificant
difference in total sleep time (-2.4 minutes; 95% CI -11.4 to
6.6). However, sleep onset latency has been demonstrated
to be significantly increased on the first night after stopping
zolpidem (13.0 minutes; 95% CI 4.3-21.7; P<0.01). After 2-4
weeks post-discontinuation, there were no signs of rebound
insomnia, and this was sustained for over 6 months.48
GENDER-RELATED DISCREPANCIES

The Food and Drug Administration (FDA) released a somewhat unsubstantiated statement in the New England Journal
of Medicine (2013) that an increased risk of sedation and driving impairment in women compared to men with the most
significant risk seen above 50ng/mL.49 This was accompanied by a recommendation for women to receive lower doses
(5mg of immediate-release [IR], 6.25mg of extended-release
[ER]).49,50 While previous studies have already demonstrated a lower clearance in women than men, the FDA recommendation on dosing was based solely on gender differences rather than weight-normalized dosing.50–52
A commentary article was published in 2019 by the Journal of Clinical Psychopharmacology using data from a double-blind, single-dose, random sequence, 3-way cross-over
study of 10mg zolpidem immediate-release (IR), 12.5mg
zolpidem extended-release (ER), and placebo.50 The gender

differences in drug concentrations at the critical point described in the original FDA release (8 hours after 10mg IR or
12.5mg ER) were measured. It was again demonstrated that
female subjects had a lower zolpidem clearance than males
(3.73mL/min/kg vs. 4.02mL/min/kg) even after adjustment
for body weight, but this was not significant (P = 0.085).
Women had a non-significantly higher mean plasma concentration than men after 8 hours for the 10mg IR (28 vs.
20 ng/mL) and the 12.5mg MR (33 vs. 28ng/mL). Women
did tend to have more frequent dose concentrations reaching or exceeding the 50ng/mL limit set by the FDA “correlating” high risk for sedation (12.5% vs. 0% in 10mg IR;
18.8% vs. 8% in 12.5mg ER).49 Importantly, there were no
difference in the Digital-Symbol Substitution Test (DSST)
scores indicative of psychomotor performance, electroencephalographic (EEG) beta amplitude indicative of drug effects, or observer-rated sedation between genders, regardless of drug concentration levels above 50ng/mL in some
subjects.50
This study highlights the illegitimacy of the FDA recommendations in 2013 to give women dosage reductions in
zolpidem to avoid sedation and driving impairment. Furthermore, the drug concentration “cut-off” of 50ng/mL for
adverse events was not proven. It is essential to pay attention to the fact that underdosing this population could
be even more hazardous, as sleep deprivation is associated
with impaired reaction time and judgement.50
PREGNANCY OUTCOMES

The FDA has classified zolpidem as a category C drug based
on adverse outcomes seen in animal fetal development. A
nationwide, population-based study compared the incidence of adverse pregnancy outcomes in mothers who had
taken zolpidem during pregnancy compared to those who
did not. The control group was adjusted for the infant’s
gender, parity, maternal educational level, gestational hypertension, gestational diabetes, pre-eclampsia/eclampsia,
and anemia. In the mothers exposed to zolpidem, there
was an increased incidence of low birth weight (OR = 1.39;
P<0.001), preterm delivery (OR 1.49; P<0.001), small for
gestational age (SGA) babies (OR = 1.34; P<0.001), and cesarean deliveries (OR =1.74; P<0.001). The rate of congenital abnormalities was not significantly increased with zolpidem (0.48 vs 0.65%; P = 0.329).53
OBSTRUCTIVE SLEEP APNEA

A double-blind, placebo-controlled, cross-over study was
performed to assess the role of hypnotics in obstructive
sleep apnea (OSA) mechanisms, such as upper airway function and breathing during sleep. Participants were randomized to either temazepam 10mg, zolpidem 10mg, zopiclone
7.5mg, or placebo, then electroencephalograms (EEGs),
electrooculogram (EOGs), and submentalis electromyograms (EMGs) were used for measurements. A pressuretipped catheter was used to determine epiglottic pressure
at the base of the tongue, and intramuscular electrodes
measured genioglossus EMG. Minute ventilation, inspiratory and expiratory time, peak inspiratory flow, and upper
airway resistance parameters in those on temazepam, zolpi-
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dem, or zopiclone were all non-significantly different from
placebo (P>0.05). The frequency of breaths per minute was
increased in all three drug groups compared to placebo
(P<0.03). Both zolpidem (27%; P=.02) and zopiclone (37%;
P<0.001) significantly increased respiratory arousal threshold compared to the placebo group, while temazepam did
not (P=0.17). None of the three drugs negatively impacted
passive upper airway collapsibility compared to placebo.
Interestingly, zolpidem paradoxically increased genioglossus muscle responsiveness to airway closure compared to
placebo (P=0.03), unlike zopiclone (P=0.98) and temazepam
(P = 0.54).54 This is a critical point, as hypnotics are usually
contraindicated in OSA. The theory that neuronal inhibition at the hypoglossal from GABA activation should cause
a decreased reflex sensitivity.54 Table 1 summarizes the results discussed in this section.
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CONCLUSION
Insomnia is a diagnosis that can be frustrating to live with,
and patients need physician support in dealing with and
treating their condition. Insomnia is linked to fatigue, distractibility, mood instability, decreased satisfaction, and
overall decreased quality of life. Optimal therapy can aid
patients in returning to baseline and increase their quality
of life. There are various lifestyle modifications, and medications available to treat insomnia—among these are patient education about avoiding caffeine intake and daytime
napping, cognitive behavioral therapy, hypnosis, sleep restriction, melatonin agonists, benzodiazepines, antidepressants, orexin receptor antagonists, and non-benzodiazepine hypnotics. Zolpidem is a helpful drug for the
treatment of insomnia in conjunction with cognitive-behavioral therapy. Like all drugs, it does have some side effects, and they are usually tolerable to patients for the payoff in increased quality of life. When prescribed to elderly
patients, the dose should be adjusted to account for their
slower drug metabolism. Still, zolpidem is considered a reasonable choice of therapy because it has a lower incidence
of residual daytime sleepiness and risk of falls when compared to other drugs. All patients should be warned about
adverse effects that can present with use, including falls
and subsequent fractures, increased risk of suicide attempts
regardless of comorbid psychiatric diagnoses, complex behaviors performed in a sleep-like state, dependence and rebound insomnia, obstructive sleep apnea, and decreases in
attention and verbal memory, and next-day impairment.
The most concerning adverse effects, which are often the
most publicized, include the complex behaviors that have
been seen in patients taking zolpidem, such as sleeping,
hallucinations, increased suicidality, driving cars while
asleep, and even a few cases of committing homicide. Prescribers should carefully weigh the potential benefits and
harms that can arise from patients taking zolpidem and
make decisions for whether or not to prescribe it as well as
the dosage on a case-by-case basis, taking into account both
the psychical and psychiatric risks posed to the patient that
has insomnia versus if the patient were to take zolpidem to
treat their condition.
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Table 1. Scientific Evidence on ADRs of Zolpidem
Author
(Year)

Groups Studied and Methods

Results and Findings

Conclusions

Stranks E. et
al. (2014)

Meta-analysis of 20 RCTs or
randomized cross-over trials
from 1980-2013 assessing
cognitive effects of zolpidem on
computerized databases
(Medline and PsycINFO).
Primary measures were Cohen’s
d effect sizes (0.2 small, 0.4
medium, and > 0.6 large) in each
cognitive domain.

Cohen’s d of -0.56 for attention
(95% CI -0.93 to -0.18), -0.46 for
verbal memory (CI -0.66 to
-0.25), -0.15 for speed of
processing (CI -0.31 to 0.02), and
-0.01 for working memory (CI
-0.17 to 0.16).

Zolpidem was associated with
moderate cognitive decline in
specific domains of attention and
verbal memory; nonsignificant
decrease in processing and
working memory speed.

Wong C. et al.
(2020)

Analysis of patient data (2, 131,
368 reports) in FAERS database
from 2003-2012 for association
of zolpidem exposure with
adverse events. Year-by-year
unadjusted odds ratios were
used as the primary measure
then adjusted for patient
demographics and cofounding
drug exposures.

OR for zolpidem exposure with
P<0.0001 for the following:
parasomnias (OR 4.34),
movement parasomnias (OR
35.20), amnesia (OR 2.78),
hallucinations (OR 1.69), and
suicidality (OR 1.70).

Zolpidem exposure was
associated with a significant
increase in ADRs of parasomnias,
amnesia, hallucinations, and
suicidality compared to placebo.

Greenblatt D.
et al. (2019)

Double-blind, single-dose,
random sequence, 3-way crossover study analyzing male and
female data from a previous
clinical pharmacokineticpharmacodynamic study of
zolpidem IR 10mg, zolpidem XR
12.5mg, and placebo; combined
these results with literature
review on adverse effects of
zolpidem.

Female subjects had lower
clearance of zolpidem than males
(3.73mL/min/kg vs. 4.02mL/min/
kg; P = 0.085). Women had
higher mean plasma
concentration than men after 8
hours for the 10mg IR (28 vs. 20
ng/mL) and the 12.5mg MR (33
vs.. 28ng/mL). No significant
difference in DSST scores, EEG
beta amplitude, or subjective
sedation scores between
genders. No correlation of 50ng/
mL concentration being the
boundary for impairment.

The FDA recommendation to
reduce the dosage of zolpidem in
women is unfounded and
unsupported by scientific
evidence. Highlights that
underdosing here could be just
as dangerous as sleep
deprivation can lead to
functional and cognitive
impairment as well.

Westermeyer
J. et al. (2020)

Post-2000 literature review of
adverse events described with
zolpidem use; the primary
measure was odds ratio. Also,
described legal impacts of some
zolpidem cases through case
reports.

Increased risk of inpatient falls
(OR 4.28; P<0.001) and fractures
(OR 1.92; P<0.001) with hip
fracture being the predominant
type. Increased suicide attempts
and completions (OR 2.0895% CI
1.65-2.24; P<0.001) regardless
of comorbid mood disorders
being present.

Zolpidem has been successfully
linked to increased falls,
fractures (hip), suicide attempts/
completions. In addition, there
have been five homicidal cases
associated (1 vehicular; 4 direct
and violent).

Stallman H.
et al. (2018)

A systematic review of
medications associated with
sleepwalking behavior using
CINAHL, EMBASE, PsychINFO,
PubMed, and ScienceDirect
databases from the original date
of each database to March 2016
was performed.

Twenty-four total studies
demonstrated the link between
zolpidem and sleepwalking; no
association with age, dosage,
history of sleepwalking, or
medical history.

Sleepwalking has been
associated with zolpidem more
frequently than any other
medication in this literature
review and is not limited to
doses exceeding 10mg or
concurrent CNS depressant use.

Andrade C. et
al. (2018)

Review of recent meta-analyses
on the risk of fractures falls, and
other injuries in those taking
zolpidem. Odds ratios were used
to measure the association of
zolpidem exposure to these
variables.

Association of zolpidem and
fractures: 2 cohort studies (OR =
2.10; 95% CI 1.76-2.49), 8 casecontrols (OR = 1.53; 95% CI
1.31-1.77), combined (OR = 1.63;
95% CI 1.42-1.87). Subgroup
analysis of z-drugs and fractures
demonstrated OR = 1.28 (95% CI
1.08-1.53) compared to the
control group with insomnia and
increased fracture risk when
restricted to age >65y was OR =
1.70 (95% CI 1.36-2.12).

Zolpidem increases the risk of
fractures in all ages and in those
>65yo and the risk of nonspecific injury compared to
controls with insomnia.
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Increased risk of non-specific
injury in those taking zolpidem
with OR = 2.05 (95% CI
1.95-2.15).
Schifano F. et
al. (2019)

Analyzed datasets describing
adverse drug reactions (misuse,
abuse, dependence, withdrawal)
with z-drugs provided by
European Medicines Agency
(EudraVigilance System).

Misuse, abuse, dependence,
withdrawal complaints made up
11.35% (95% CI 11.21-11.49%)
of total ADRs associated with
zolpidem. There were higher
rates of fatal outcomes with
these types of ADRs in zolpidem
(20.3%) compared to zopiclone
(9.33%) and zaleplon (1.1%).

Zolpidem ADRs are significantly
made up of specific misuse,
abuse, withdrawal, and
dependence complaints; the
outcomes of these
manifestations are more
frequently fatal than other zdrugs.

Vigneau C. et
al. (2014)

Post-marketing period
(2003-2010) data collected by
national CEIP network
demonstrating records of
dependence or abuse and
literature analysis. Thirty case
reports data and characteristics
were analyzed.

There were consistent yearly
increases in the number of
suspicious prescriptions for
zolpidem suspected to be
falsified during the time period.
In addition, case report analysis
demonstrated average age of 38
years old in abusers, average
daily dose of 616.1mg/d,
comorbid psychiatric disorders
in 13.3%, and comorbid
substance abuse in 40%.

Zolpidem was the number one
drug falsified in prescriptions
during the study period. In
addition, abusers take an
extremely high average daily
dose of 616.1mg, suggesting
significant dependence with
chronic users.

Licata S. et al.
(2011)

Double-blind, placebocontrolled study on 11 healthy
volunteers without personal or
family history of substance
abuse; participants were given
either 0, 5, 10, or 20mg zolpidem
then given subjective
assessments (ARCI, VAS, Drug v
Money). Two-way repeated
ANOVAs, one-way ANOVA, and
t-tests were used to measure.

In the ARCI, PCAG
(F(3, 30) = 6.68, p < 0.001) and
BG (F(3,30) = 4.77, p < 0.01)
were both found to be
associated with zolpidem use.
On VAS, “sleepy”
(F(3, 330) = 12.93, p < 0.001),
“high”
(F(3, 330) = 9.95, p < 0.001), and
“good effects”
(F(3, 330)13.53, p < 0.001) were
most reported at the highest
doses. Drug v. Money always
resulted in the choice of money
relative to placebo regardless of
monetary value.

Zolpidem most commonly causes
subjective feelings of
intoxication or stimulant-like
effects. Feelings of being high
and abuse-related effects were
seen more at higher doses, even
in drug-naïve patients. Despite
these effects, it had no impact on
the hypothetical choice of money
vs. zolpidem (patients would
rather receive $0.35 over
another zolpidem dose).

Wang L. et al.
(2010)

Nationwide, a population-based
study looking at the incidence of
adverse outcomes of pregnancy
in mothers taking zolpidem
during pregnancy compared to
those who did not.

Zolpidem use in mothers had an
increased incidence of low birth
weight (OR = 1.39; P<0.001),
preterm delivery (OR 1.49;
P<0.001), SGA babies (OR =
1.34; P<0.001), and cesarean
deliveries (OR =1.74; P<0.001)
compared to mothers who did
not use zolpidem. The rate of
congenital abnormalities was not
significantly increased with
zolpidem (0.48 vs 0.65%; P =
0.329).

Zolpidem use in pregnancy is not
associated with an increased risk
of congenital abnormalities (not
a teratogen). However, there are
increased risks associated with
zolpidem use, such as SGA
babies, preterm delivery, LBW
babies, and C-sections.

Carberry C.
et al. (2017)

Double-blind, placebocontrolled, cross-over study;
Participants were randomized to
either temazepam 10mg,
zolpidem 10mg, zopiclone 7.5mg,
or placebo, then EEGs, EOGs,
EMGs were used for sleep stage
determination. In addition, a
pressure-tipped catheter was
used for epiglottic pressure at
the base of the tongue, and
intramuscular electrodes
measured genioglossus EMG.

Minute ventilation, inspiratory
and expiratory time, peak
inspiratory flow, and upper
airway resistance parameters in
all three groups were
nonsignificant from placebo
(P>0.05). The frequency of
breaths/min was increased in all
three drug groups compared to
placebo (P<0.03). Both zolpidem
(27%; P=.02) and zopiclone
(37%; P<0.001) significantly
increased respiratory arousal
threshold compared to the
placebo group. Temazepam did
not (P=0.17). No impact on

Zolpidem causes a paradoxical
increase in airway
responsiveness to passive upper
airway collapsibility, calling into
question the common theory of
hypnotics worsening OSA. In
addition, Z-drugs increased
respiratory arousal when
compared to placebo and
benzodiazepines.
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passive upper airway
collapsibility compared to
placebo in any group. Zolpidem
increased genioglossus muscle
responsiveness compared to
placebo (P=0.03) unlike
zopiclone (P=0.98) and
temazepam (P = 0.54).
MacFarlane
J. et al. (2014)

Review of the efficacy of
zolpidem in the treatment of
insomnia and safety of zolpidem
by searching PubMed and
Google Scholar.

The first-night postdiscontinuation of zolpidem,
there was a nonsignificant
difference in total sleep time
(-2.4 min; 95% CI -11.4 to 6.6). In
addition, SOL was increased on
the first night after stopping
zolpidem (13.0 minutes; 95% CI
4.3-21.7; P<0.01). After 2-4
weeks post-discontinuation,
there were no signs of rebound
insomnia.

It does not appear that rebound
insomnia is sustained in patients
after discontinuation of
zolpidem, though it may be
present acutely.

Ito S. et al.
(2007)

Double-blind cross-over study
comparing psychomotor effects
of 10mg zolpidem to placebo by
measuring combined test for
finger dexterity (CTFD), CFF,
simple discriminatory reaction
tests (SDRs), and fifty-meter
sprint.

An only significant difference
between groups was seen in CFF
where the zolpidem group had
better results than placebo
F=8.5 (P=0.03).

Zolpidem can be used in healthy
adults or athletes to improve
sleep without significant
psychomotor function or
physical performance deficits.

Mahoney J.
et al. (2004)

Case series of 50-year-old
inpatients (n=119) from
1993-1997 who received
zolpidem during hospitalization
assessing for ADRs related to
zolpidem use.

21 out of 26 ADRs were CNSrelated (80.8%) and occurring in
doses of 5mg or 10mg; Patients
having a baseline functional
impairment were at significant
risk of CNS ADRs (P=0.003).

Inpatient use of zolpidem is
associated with a high risk of
CNS ADRs and should be used
with caution in those with
underlying functional
impairment.
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